Cencora raises adjusted EPS guidance and Cencora stock costs EUR 284.25
Published on 10/08/2026 at 15:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora Inc. (ISIN US03073E1055) raised its fiscal 2026 adjusted earnings per share guidance to USD 17.75-17.95 from USD 17.70-17.90, while Cencora stock costs EUR 284.25 at Lang & Schwarz on October 8, 2026 at 3:04 p.m. CEST. Benzinga reported the guidance change on October 8, 2026, giving investors a fresh measure of the distributor's earnings trajectory.
Guidance rises with third-quarter growth
In fiscal third quarter 2026, revenue reached USD 84.8 billion, up 5.00 percent from the prior-year quarter, according to Benzinga. Adjusted operating income grew 17.00 percent, while adjusted earnings per share increased 12.00 percent.
The revised guidance lifted both ends of the previous range by USD 0.05. The call also cited USD 1 billion of share repurchases during the quarter, a capital-allocation factor that supported the adjusted earnings per share growth.
What does the guidance change mean?
The main operating signal is the combination of revenue growth and stronger profitability. Adjusted gross profit reached USD 3.5 billion, up 23.00 percent year over year, while consolidated adjusted operating income reached USD 1.2 billion, up 17.00 percent, according to Benzinga. U.S. Healthcare Solutions revenue was USD 74.9 billion, up 5.00 percent, and the segment's operating income rose 16.00 percent to USD 966 million.
The counter-factor is cost and policy sensitivity. Management said manufacturer list-price reductions created a USD 2.4 billion headwind to revenue growth in the quarter, while GLP-1 sales increased by USD 2.3 billion year over year.
Three milestones frame the update
On September 2, 2026, Cencora listed a press release on cell and gene therapy enablement for health systems; its website says the company operates in over 50 countries, according to Cencora. On September 25, 2026, the company announced Robert E. Sanchez would join its board effective October 1, 2026, according to Business Wire. On October 8, 2026, the company raised fiscal 2026 adjusted earnings per share guidance to USD 17.75-17.95.
Next date is November 4
Business Wire said Cencora will release fiscal fourth-quarter 2026 results on November 4, 2026, before the New York Stock Exchange opens, with a conference call at 8:30 a.m. ET.
Stock holds a narrow daily gain
Cencora stock was trading at EUR 284.25 at Lang & Schwarz on October 8, 2026 at 3:04 p.m. CEST, up 0.32 percent versus the Lang & Schwarz prior close of EUR 283.35. The primary listing is on the NYSE, where the finance quote was last at USD 317.25 on October 7, 2026 at 4:00 p.m. ET, against a 52-week range of USD 244.82-377.54 and a market capitalization of USD 61.7 billion.
The further course of trading is shown by the continuously updated real-time quote of Cencora stock.
Cencora stock facts
- Company: Cencora, Inc.
- ISIN: US03073E1055
- Ticker: COR
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 8, 2026, 3:04 p.m. CEST): EUR 284.25
- Change versus prior close: plus 0.32 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 283.35
- Market capitalization: USD 61.7 billion (as of October 7, 2026)
- 52-week range: USD 244.82-377.54 (as of October 7, 2026)
- Sector / Industry: Healthcare / Medical - Distribution
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
